Updating results

34 results for urinary tract infections

Sort: Relevance | Date

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

UroShield for preventing catheter-associated urinary tract infections (MIB191)

Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making

Medtech innovation briefing Published September 2019

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Farco-fill Protect for indwelling urinary catheterisation (MIB121)

Advice on the use of Farco-fill Protect for inflating Foley catheter balloons for indwelling (in-situ) urinary catheterisation to aid local decision-making

Medtech innovation briefing Published September 2017

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

Advice on the use of Memokath-028, 044 and 045 stents for urethral obstruction and bladder neck or outlet obstructions in men to aid local decision-making

Medtech innovation briefing Published October 2017

MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)

Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making

Medtech innovation briefing Published October 2019

Peezy Midstream for urine collection (MIB183)

Advice on Peezy Midstream for midstream urine (MSU) collection

Medtech innovation briefing Published May 2019

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Antimicrobial stewardship: prescribing antibiotics (KTT9)

NICE/PHE summary of antimicrobial prescribing guidance – managing common infections , PHE guidance Start smart − then focus , local...

Key therapeutic topic Published January 2015 Last updated September 2019

ADXBLADDER for detecting bladder cancer (MIB180)

Advice on ADXBLADDER for detecting bladder cancer to aid local decision making

Medtech innovation briefing Published April 2019

Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)

KTT10 KTT10

Key therapeutic topic Published January 2015 Last updated February 2016

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

Advice on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume to aid local decision-making

Medtech innovation briefing Published January 2016

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Rezum for treating benign prostatic hyperplasia (MIB158)

Advice on the use of Rezum (NxThera Inc) for treating benign prostatic hyperplasia (BPH) to aid local decision-making

Medtech innovation briefing Published August 2018

S-Cath System for suprapubic catheterisation (MIB68)

Advice on the use of the S-Cath System for suprapubic catheterisation to aid local decision-making

Medtech innovation briefing Published June 2016

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

Evidence summary Published July 2013

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

The NGAL Test for early diagnosis of acute kidney injury (MIB3)

Advice on the use of the NGAL Test for early diagnosis of acute kidney injury (AKI) to aid local decision-making

Medtech innovation briefing Published February 2014

Secca System for faecal incontinence (MIB66)

Advice on the use of the Secca system for treating faecal incontinence to aid local decision-making

Medtech innovation briefing Published May 2016

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

Advice on the MiniMed 640G system with SmartGuard for managing blood glucose levels in type 1 diabetes to aid local decision-making

Medtech innovation briefing Published February 2016

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Urethrotech UCD for difficult or failed catheterisation (MIB116)

Advice on the use of Urethrotech urethral catheterisation device (UCD) for difficult or failed catheterisations in men to aid local decision-making

Medtech innovation briefing Published August 2017

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Type 2 diabetes: alogliptin (ESNM20)

Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published May 2013 Last updated October 2014

Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

Advice on the use of the Xpert GBS test for the intrapartum detection of group B streptococcus (GBS) colonisation in pregnant women...

Medtech innovation briefing Published April 2015

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015